1. **INTRODUCTIONS**
   
a. Welcoming new working group members  
   i. Charles Wiysonge, Cochrane South Africa, South African Medical Research Council, South Africa

2. **FOLLOW-UP ON ACTION ITEMS**
   
a. Consider whether “Scoping” name best reflects the evolving purpose of group  
   i. Perhaps include statement in terms of reference describing expected evolution of group’s role in helping guide COVID-END initiatives  
   ii. Review the message, value and offers of COVID-END

3. **DISCUSSION ON WORKING GROUP ACTIVITIES**
   
a. Draft logic model for COVID-END (see attachment 3)  
b. Working groups to identify narrow objectives in their scopes that may have some attached timelines, in order to achieve some “quick wins”

4. **ENGAGING WITH OTHER GROUPS AND ORGANIZATIONS**
   
a. Discussing questions brought up by Digitizing working group  
   i. What do you see as the biggest blocker to your work right now?  
   ii. What is your biggest technical blocker?  
b. Any additional organizations that are currently supporting decision-makers from list shared by Engaging working group  
   i. 3IE  
   ii. Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Centers  
   iii. Africa Evidence Network, which includes groups like:  
      • Africa Centre for Evidence, University of Johannesburg  
      • Centre for Rapid Evidence Synthesis, Makerere University  
   iv. Centre for Learning and Evaluation Results  
   v. Cochrane Geographic Groups:  
      • Cochrane US Network (4 EPCs are members)  
   vi. Collaboration for Environmental Evidence  
   vii. Evidence Aid (UK)  
   viii. EVIPNet
<table>
<thead>
<tr>
<th>x. National Collaborating Centres +/- SPOR Support Units (Canada)</th>
</tr>
</thead>
<tbody>
<tr>
<td>xi. What Works Centres (UK), which includes groups like:</td>
</tr>
<tr>
<td>• Education Endowment Initiative</td>
</tr>
<tr>
<td>xi. Global Evidence Synthesis Initiative (GESI)</td>
</tr>
</tbody>
</table>

5. **ANY OTHER BUSINESS**

2 min